ABUS vs MCK · P/E 5.4, rev $6.2M vs P/E 20, rev $403.43B
Arbutus Biopharma Corp (ABUS) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the ABUS and MCK stock pages for the full models.
Not investment advice.